BeiGene (BSP:B1GN34) Equity-to-Asset

: 0.61 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BeiGene's Total Stockholders Equity for the quarter that ended in Dec. 2023 was R$17,332 Mil. BeiGene's Total Assets for the quarter that ended in Dec. 2023 was R$28,445 Mil. Therefore, BeiGene's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.61.

The historical rank and industry rank for BeiGene's Equity-to-Asset or its related term are showing as below:

BSP:B1GN34' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48 Med: 0.66 Max: 0.87
Current: 0.61

During the past 11 years, the highest Equity to Asset Ratio of BeiGene was 0.87. The lowest was 0.48. And the median was 0.66.

BSP:B1GN34's Equity-to-Asset is ranked worse than
54.73% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs BSP:B1GN34: 0.61

BeiGene Equity-to-Asset Historical Data

The historical data trend for BeiGene's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

0.60

0.69

0.72

0.69

0.61

BeiGene Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset																0.69	0.70	0.66	0.68	0.61

Competitive Comparison

For the Biotechnology subindustry, BeiGene's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BeiGene Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, BeiGene's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where BeiGene's Equity-to-Asset falls into.

BeiGene Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

BeiGene's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	17332.195	/	28444.686
	=	0.61

BeiGene's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	17332.195	/	28444.686
	=	0.61

BeiGene (BSP:B1GN34) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

BeiGene Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of BeiGene's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (BSP:B1GN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (BSP:B1GN34) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

BGNE:USA 06160:Hong Kong 49BA:Germany 688235:China

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (BSP:B1GN34) Headlines

No Headlines